These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26554912)

  • 1. Genetic Evidence for XPC-KRAS Interactions During Lung Cancer Development.
    Zhang X; He N; Gu D; Wickliffe J; Salazar J; Boldogh I; Xie J
    J Genet Genomics; 2015 Oct; 42(10):589-596. PubMed ID: 26554912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model.
    Weng TY; Yen MC; Huang CT; Hung JJ; Chen YL; Chen WC; Wang CY; Chang JY; Lai MD
    Gene Ther; 2014 Oct; 21(10):888-96. PubMed ID: 25077772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
    Alamo P; Gallardo A; Di Nicolantonio F; Pavón MA; Casanova I; Trias M; Mangues MA; Lopez-Pousa A; Villaverde A; Vázquez E; Bardelli A; Céspedes MV; Mangues R
    FASEB J; 2015 Feb; 29(2):464-76. PubMed ID: 25359494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. XPC protects against smoking- and carcinogen-induced lung adenocarcinoma.
    Zhou H; Saliba J; Sandusky GE; Sears CR
    Carcinogenesis; 2019 May; 40(3):403-411. PubMed ID: 30624620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse models for xeroderma pigmentosum group A and group C show divergent cancer phenotypes.
    Melis JP; Wijnhoven SW; Beems RB; Roodbergen M; van den Berg J; Moon H; Friedberg E; van der Horst GT; Hoeijmakers JH; Vijg J; van Steeg H
    Cancer Res; 2008 Mar; 68(5):1347-53. PubMed ID: 18316597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting UHRF1-dependent DNA repair selectively sensitizes KRAS mutant lung cancer to chemotherapy.
    Tian D; Tang J; Geng X; Li Q; Wang F; Zhao H; Narla G; Yao X; Zhang Y
    Cancer Lett; 2020 Nov; 493():80-90. PubMed ID: 32814087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Xeroderma pigmentosum group C gene expression is predominantly regulated by promoter hypermethylation and contributes to p53 mutation in lung cancers.
    Wu YH; Tsai Chang JH; Cheng YW; Wu TC; Chen CY; Lee H
    Oncogene; 2007 Jul; 26(33):4761-73. PubMed ID: 17325666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
    Green S; Trejo CL; McMahon M
    Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo.
    Elsum IA; Yates LL; Pearson HB; Phesse TJ; Long F; O'Donoghue R; Ernst M; Cullinane C; Humbert PO
    Oncogene; 2014 Nov; 33(48):5523-33. PubMed ID: 24276238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
    Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
    Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 dysfunction by xeroderma pigmentosum group C defects enhance lung adenocarcinoma metastasis via increased MMP1 expression.
    Wu YH; Wu TC; Liao JW; Yeh KT; Chen CY; Lee H
    Cancer Res; 2010 Dec; 70(24):10422-32. PubMed ID: 21056989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of xeroderma pigmentosum C (Xpc) enhances melanoma photocarcinogenesis in Ink4a-Arf-deficient mice.
    Yang G; Curley D; Bosenberg MW; Tsao H
    Cancer Res; 2007 Jun; 67(12):5649-57. PubMed ID: 17575131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung Cancer Onset in Wild Type Mice Following Bone Marrow Reconstitution with kras(v12) Cells.
    Belloni E; Martin Padura I; Gerbino E; Orecchioni S; Fusar Imperatore F; Marighetti P; Bertalot G; Giuseppe Pelicci P; Bertolini F
    Sci Rep; 2015 Aug; 5():13047. PubMed ID: 26267334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTEN loss and KRAS activation leads to the formation of serrated adenomas and metastatic carcinoma in the mouse intestine.
    Davies EJ; Marsh Durban V; Meniel V; Williams GT; Clarke AR
    J Pathol; 2014 May; 233(1):27-38. PubMed ID: 24293351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
    Ji H; Wang Z; Perera SA; Li D; Liang MC; Zaghlul S; McNamara K; Chen L; Albert M; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Thomas RK; Garraway LA; Jänne PA; Johnson BE; Chin L; Wong KK
    Cancer Res; 2007 May; 67(10):4933-9. PubMed ID: 17510423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational inactivation of the xeroderma pigmentosum group C gene confers predisposition to 2-acetylaminofluorene-induced liver and lung cancer and to spontaneous testicular cancer in Trp53-/- mice.
    Cheo DL; Burns DK; Meira LB; Houle JF; Friedberg EC
    Cancer Res; 1999 Feb; 59(4):771-5. PubMed ID: 10029060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer.
    Li K; Liu Y; Ding Y; Zhang Z; Feng J; Hu J; Chen J; Lian Z; Chen Y; Hu K; Chen Z; Cai Z; Liu M; Pang X
    J Clin Invest; 2022 Nov; 132(22):. PubMed ID: 36377663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.
    Uvirova M; Simova J; Kubova B; Dvorackova N; Tomaskova H; Sedivcova M; Dite P
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):466-71. PubMed ID: 26077004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade.
    Umelo IA; De Wever O; Kronenberger P; Van Deun J; Noor A; Singh K; Teugels E; Chen G; Bracke M; De Grève J
    Oncotarget; 2015 Aug; 6(24):20132-44. PubMed ID: 25992771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced XPC messenger RNA level may predict a poor outcome of patients with nonsmall cell lung cancer.
    Wu YH; Cheng YW; Chang JT; Wu TC; Chen CY; Lee H
    Cancer; 2007 Jul; 110(1):215-23. PubMed ID: 17508409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.